View in EDS

Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.

Saved in:
Bibliographic Details
Title: Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
Authors: Humphreys J; Epiconcept, Paris, France. Electronic address: j.humphreys@epiconcept.fr., Blake A; Epiconcept, Paris, France., Nicolay N; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Braeye T; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium., Van Evercooren I; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium., Hansen CH; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Moustsen-Helms IR; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Sacco C; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden., Mateo-Urdiales A; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy., Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain., Machado A; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal., Brito A; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal., Ljung R; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Pihlstrom N; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Mansiaux Y; Epiconcept, Paris, France., Monge S; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain; CIBER on Infectious Diseases, Spain., Bacci S; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Nunes B; Epiconcept, Paris, France.
Corporate Authors: VEBIS-EHR working group
Source: Vaccine [Vaccine] 2025 Oct 03; Vol. 64, pp. 127752. Date of Electronic Publication: 2025 Sep 19.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40974735
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Humphreys+J%22">Humphreys J</searchLink>; Epiconcept, Paris, France. Electronic address: j.humphreys@epiconcept.fr.<br /><searchLink fieldCode="AU" term="%22Blake+A%22">Blake A</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Nicolay+N%22">Nicolay N</searchLink>; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Braeye+T%22">Braeye T</searchLink>; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+Evercooren+I%22">Van Evercooren I</searchLink>; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium.<br /><searchLink fieldCode="AU" term="%22Hansen+CH%22">Hansen CH</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Moustsen-Helms+IR%22">Moustsen-Helms IR</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Sacco+C%22">Sacco C</searchLink>; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Mateo-Urdiales+A%22">Mateo-Urdiales A</searchLink>; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Castilla+J%22">Castilla J</searchLink>; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez-Baz+I%22">Martínez-Baz I</searchLink>; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain.<br /><searchLink fieldCode="AU" term="%22Machado+A%22">Machado A</searchLink>; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal.<br /><searchLink fieldCode="AU" term="%22Brito+A%22">Brito A</searchLink>; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal.<br /><searchLink fieldCode="AU" term="%22Ljung+R%22">Ljung R</searchLink>; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Pihlstrom+N%22">Pihlstrom N</searchLink>; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Mansiaux+Y%22">Mansiaux Y</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Monge+S%22">Monge S</searchLink>; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain; CIBER on Infectious Diseases, Spain.<br /><searchLink fieldCode="AU" term="%22Bacci+S%22">Bacci S</searchLink>; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.<br /><searchLink fieldCode="AU" term="%22Nunes+B%22">Nunes B</searchLink>; Epiconcept, Paris, France.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22VEBIS-EHR+working+group%22">VEBIS-EHR working group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2025 Oct 03; Vol. 64, pp. 127752. <i>Date of Electronic Publication: </i>2025 Sep 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40974735
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2025.127752
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 127752
    Titles:
      – TitleFull: Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Humphreys J
      – PersonEntity:
          Name:
            NameFull: Blake A
      – PersonEntity:
          Name:
            NameFull: Nicolay N
      – PersonEntity:
          Name:
            NameFull: Braeye T
      – PersonEntity:
          Name:
            NameFull: Van Evercooren I
      – PersonEntity:
          Name:
            NameFull: Hansen CH
      – PersonEntity:
          Name:
            NameFull: Moustsen-Helms IR
      – PersonEntity:
          Name:
            NameFull: Sacco C
      – PersonEntity:
          Name:
            NameFull: Mateo-Urdiales A
      – PersonEntity:
          Name:
            NameFull: Castilla J
      – PersonEntity:
          Name:
            NameFull: Martínez-Baz I
      – PersonEntity:
          Name:
            NameFull: Machado A
      – PersonEntity:
          Name:
            NameFull: Brito A
      – PersonEntity:
          Name:
            NameFull: Ljung R
      – PersonEntity:
          Name:
            NameFull: Pihlstrom N
      – PersonEntity:
          Name:
            NameFull: Mansiaux Y
      – PersonEntity:
          Name:
            NameFull: Monge S
      – PersonEntity:
          Name:
            NameFull: Bacci S
      – PersonEntity:
          Name:
            NameFull: Nunes B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 10
              Text: 2025 Oct 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 64
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1